2016
DOI: 10.1016/j.ajo.2016.03.038
|View full text |Cite
|
Sign up to set email alerts
|

Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
26
0
1

Year Published

2016
2016
2024
2024

Publication Types

Select...
7

Relationship

4
3

Authors

Journals

citations
Cited by 30 publications
(28 citation statements)
references
References 21 publications
1
26
0
1
Order By: Relevance
“…We previously reported 60% of eyes with resistant AMD while on Q4W ranibizumab or bevacizumab respond well to 2Q8W aflibercept, 7 and the macula was dry for up to 2 years after switching to 2Q8W aflibercept. 8 We also found that approximately 45% of eyes needed to be escalated from 2Q8W to 2Q4W aflibercept because of persistent fluid, and some of these patients still did not respond very well to monthly 2 mg aflibercept. 8 In these cases, we initiated a double-dose 4Q4W aflibercept treatment regimen.…”
mentioning
confidence: 74%
See 2 more Smart Citations
“…We previously reported 60% of eyes with resistant AMD while on Q4W ranibizumab or bevacizumab respond well to 2Q8W aflibercept, 7 and the macula was dry for up to 2 years after switching to 2Q8W aflibercept. 8 We also found that approximately 45% of eyes needed to be escalated from 2Q8W to 2Q4W aflibercept because of persistent fluid, and some of these patients still did not respond very well to monthly 2 mg aflibercept. 8 In these cases, we initiated a double-dose 4Q4W aflibercept treatment regimen.…”
mentioning
confidence: 74%
“… 8 We also found that approximately 45% of eyes needed to be escalated from 2Q8W to 2Q4W aflibercept because of persistent fluid, and some of these patients still did not respond very well to monthly 2 mg aflibercept. 8 In these cases, we initiated a double-dose 4Q4W aflibercept treatment regimen. In the current study, we retrospectively evaluate the efficacy of 4Q4W (high dose high frequency) aflibercept intravitreal injections in patients with wet AMD resistant to other anti-VEGF treatments.…”
mentioning
confidence: 74%
See 1 more Smart Citation
“…However, in VIEW 1-2 trials [3], aflibercept was found to be non-inferior to ranibuzumab treatment of naïve neovascular AMD patients. In our previous series, aflibercept was also effective in persistent neovascular age-related macular degeneration patients who failed monthly bevacizumab and/or ranibizumab injections over a 2-year follow-up [4].…”
mentioning
confidence: 83%
“…We previously reported 60% of eyes with resistant AMD while on Q4W ranibizumab or bevacizumab responded well to 2Q8W aflibercept, 6 and the macula was dry for up to 2 years after switching to 2Q8W aflibercept. 7 Recently, we also reported the results of 2Q4W aflibercept treatment. 8 Drs.…”
mentioning
confidence: 97%